Thus, the development of more effective ATP-competitive inhibitors for MEK, or of new allosteric inhibitors that fit the deformed allosteric pocket, is of paramount importance for the treatment of human cancers with MEK mutations such as lung and colon cancers, and melanomas. This evidence concerns the gene MAP2K7 and malignant colon neoplasm.